<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
(Mark One)
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
- ---
ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 1997.
------------------
- ---TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO .
------ -----
Commission file number: 0-21145
COVALENT GROUP, INC.
(Name of small business issuer in its charter)
NEVADA 56-1668867
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
ONE GLENHARDIE CORPORATE CENTER, 1275 DRUMMERS LANE
Wayne, Pennsylvania 19087
(address of principal executive offices)
Issuer's telephone number: 610-975-9533
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes X No
--- ---
State the number of shares outstanding of each of the issuer's classes of common
equity as of October 31, 1997.
Common Stock, Par Value $.001 11,700,914
- ----------------------------- ----------
(Class) Outstanding
Transitional Small Business Disclosure Format (check one): Yes No X
--- ---
1
<PAGE>
FORM 10-QSB
COVALENT GROUP, INC.
INDEX
Page(s)
-------
PART I. Financial Information
Item 1. Consolidated Financial Statements
Balance Sheet - September 30, 1997 (Unaudited) 3-4
Statements of Operations - Three and Nine
Months Ended September 30, 1997 and 1996 (Unaudited) 5
Statements of Cash Flows - Nine Months
Ended September 30, 1997 and 1996 (Unaudited) 6
Notes to Consolidated Financial Statements
(Unaudited) 7-8
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations 9-12
PART II. Other Information 13
Signature Page 14
2
<PAGE>
PART I. FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
COVALENT GROUP, INC.
AND SUBSIDIARY
CONSOLIDATED BALANCE SHEET
SEPTEMBER 30, 1997
(Unaudited)
ASSETS
CURRENT ASSETS
<S> <C>
Cash and cash equivalents $2,081,986
Accounts receivable 1,107,367
Note receivable, current 37,500
Interest receivable 11,812
Prepaid expenses 169,794
Deferred income taxes 156,167
Costs and estimated earnings in excess
related billings on uncompleted contracts 2,531,159
----------
TOTAL CURRENT ASSETS 6,095,785
----------
PROPERTY AND EQUIPMENT
Equipment 779,300
Furniture & fixtures 186,532
Leasehold improvements 59,441
----------
1,025,273
Less - Accumulated depreciation (326,172)
----------
NET PROPERTY AND EQUIPMENT 699,101
----------
OTHER ASSETS
Note receivable, less current portion 187,500
Other 12,396
----------
TOTAL OTHER ASSETS 199,896
----------
TOTAL ASSETS $6,994,782
==========
See accompanying notes to financial statements
</TABLE>
3
<PAGE>
<TABLE>
<CAPTION>
COVALENT GROUP, INC.
AND SUBSIDIARY
CONSOLIDATED BALANCE SHEET
SEPTEMBER 30, 1997
(Unaudited)
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
<S> <C>
Accounts payable $ 2,593,077
Accrued liabilities 34,414
Billings in excess of related costs and
estimated earnings on uncompleted contracts 247,878
-----------
TOTAL CURRENT LIABILITIES 2,875,369
-----------
STOCKHOLDERS' EQUITY
Common stock, $.001 par value per
share, 25,000,000 shares authorized,
11,700,914 shares issued and outstanding 11,701
Additional paid-in-capital 9,169,279
Accumulated deficit (5,061,567)
TOTAL STOCKHOLDERS' EQUITY 4,119,413
-----------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 6,994,782
===========
See accompanying notes to financial statements
</TABLE>
4
<PAGE>
<TABLE>
<CAPTION>
COVALENT GROUP, INC.
and Subsidiary
Consolidated Statements Of Operations
(Unaudited)
THREE MONTHS ENDED Nine Months Ended
SEPTEMBER 30, September 30,
--------------------------- -------------------------------
1997 1996 1997 1996
------ ------ ------ ------
<S> <C> <C> <C> <C>
REVENUES $3,545,236 $2,686,690 $9,858,680 $6,622,841
COST OF REVENUES 2,162,063 1,624,324 7,024,257 3,796,824
---------- ---------- ---------- ----------
GROSS PROFIT 1,383,173 1,062,366 2,834,423 2,826,017
---------- ---------- ---------- ----------
OPERATING EXPENSES
Selling, general and administrative 583,712 556,665 1,765,708 1,505,445
Research and development 443,422 291,123 864,392 590,080
---------- ---------- ---------- ----------
TOTAL OPERATING EXPENSES 1,027,134 847,788 2,630,100 2,095,525
---------- ---------- ---------- ----------
INCOME FROM OPERATIONS 356,039 214,578 204,323 730,492
INTEREST INCOME 32,698 29,431 82,996 62,535
---------- ---------- ---------- ----------
INCOME FROM CONTINUING
OPERATIONS BEFORE INCOME TAXES 388,737 244,009 287,319 793,027
INCOME TAX PROVISION (BENEFIT) 66,754 - (36,754) -
------- ---------- ---------- ----------
INCOME FROM CONTINUING
OPERATIONS 321,983 244,009 324,073 793,027
DISCONTINUED OPERATIONS
Loss from operations - (36,201) - (157,176)
Loss on disposal - (301,660) - (301,660)
---------- ---------- ---------- ----------
NET INCOME(LOSS) $ 321,983 $ (93,852) $ 324,073 $ 334,191
========== ========== ========== ==========
NET INCOME(LOSS) PER COMMON AND
Common Equivalent Shares $ .03 $ (.01) $ .03 $ .03
========== ========== ========== ==========
WEIGHTED AVERAGE COMMON AND
COMMON EQUIVALENT SHARES
OUTSTANDING 12,482,710 11,542,362 12,106,773 11,971,340
========== ========== ========== ==========
See accompanying notes to financial statements.
</TABLE>
5
<PAGE>
<TABLE>
<CAPTION>
COVALENT GROUP, INC.
AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
NINE MONTHS ENDED
September 30,
-------------------------------------
1997 1996
------------ -------------
<S> <C> <C>
Cash Flows From Operating Activities:
Net income $ 324,073 $ 334,191
Adjustments to reconcile net income to
net cash provided by operating activities
Amortization and depreciation 124,836 101,936
Loss on disposal of subsidiary - 301,660
Changes In assets and liabilities
(Increase) decrease in -
Accounts receivable 2,026,424 (420,633)
Interest receivable (11,812) -
Prepaid expenses (87,145) 3,286
Deferred taxes (59,804) -
Costs and estimated earnings in excess
of related billings on uncompleted contracts (2,531,159) (1,325,635)
Other assets (4,042) (542)
Increase (decrease) in -
Accounts payable 1,905,146 572,921
Accrued liabilities 25,847 -
Billings in excess of related costs and
estimated earnings on uncompleted contracts (337,990) 679,500
----------- ------------
NET CASH PROVIDED BY OPERATING ACTIVITIES 1,374,374 246,684
----------- ------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment (300,143) (248,384)
Net change in assets of discontinued operations - (199,893)
----------- ------------
NET CASH USED IN INVESTING ACTIVITIES (300,143) (448,277)
----------- ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of stock, net 85,745 1,910,512
----------- ------------
NET CASH PROVIDED BY FINANCING ACTIVITIES 85,745 1,910,512
----------- ------------
NET INCREASE IN CASH AND CASH EQUIVALENTS 1,159,976 1,708,919
CASH AND CASH EQUIVALENTS, BEGINNING 922,010 298,583
----------- ------------
CASH AND CASH EQUIVALENTS, ENDING $ 2,081,986 $ 2,007,502
=========== ============
</TABLE>
See accompanying notes to financial statements
6
<PAGE>
FORM 10-QSB
COVALENT GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Description of Business
-----------------------
Covalent Group, Inc. (the "Company"), formerly Future Medical Technologies
International, Inc., is a contractual research organization, providing
clinical research and development services to pharmaceutical,
biotechnology, medical services and managed care organizations. The
Company initiates, designs and monitors clinical trials, manages and
analyzes clinical data and offers other related services and products.
2. Summary of Significant Accounting Policies
------------------------------------------
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses
during the period. Actual results could differ from those estimates.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company
and its wholly owned subsidiary. Intercompany transactions and balances
have been eliminated in consolidation.
Basis of Presentation
The financial statements for the nine months ended September 30, 1997 have
been prepared without audit and, in the opinion of management, reflect all
adjustments necessary (consisting only of normal recurring adjustments) to
present fairly the Company's financial position at September 30, 1997 and
the results of its operations and its cash flows for the interim and
cumulative periods presented. Such financial statements do not include all
of the information and footnotes required by generally accepted accounting
principles for complete financial statements. For further information,
refer to the financial statements and footnotes thereto included in the
Company's annual report on Form 10-KSB for the year ended December 31,
1996.
Operating results for the nine months ended September 30, 1997 may not
necessarily be indicative of the results for the year ending December 31,
1997.
7
<PAGE>
Revenue Recognition
Fixed price contract revenue is recognized using the percentage of
completion method based on the ratio of costs incurred to date to estimated
total costs at completion. Revenue from other contracts is recognized as
services are provided. Revenue related to contract modifications is
recognized when realization is assured and the amounts are reasonably
determinable. Adjustments to contract cost estimates are made in the
periods in which the facts which require the revisions become known. When
the revised estimate indicated a loss, such loss is provided for currently
in its entirety. Unbilled accounts receivable, included in accounts
receivable, represent revenue recognized in excess of amounts billed.
Advance billings represent amounts billed in excess of revenue recognized.
Reclassification
Certain prior year balances have been reclassified to conform to current
year presentation.
Earnings Per Share
In February 1997, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 128, "Earnings per
Share", which the Company is required to adopt for both interim and annual
periods ending after December 15, 1997. SFAS No. 128 simplifies the EPS
calculation by replacing primary EPS with basic EPS and replacing fully
diluted EPS with diluted EPS. Basic EPS is computed by dividing reported
earnings available to common shareholders by the weighted average shares
outstanding. Diluted EPS reflects the potential dilution from the exercise
or conversion of securities into common stock, such as stock options and
warrants. Early application is prohibited, although footnote disclosure of
pro forma EPS amounts are required. Pro forma basic EPS and diluted EPS
would have been $.03 and $.03, respectively, for the three months ended
September 30, 1997 and $.03 and $.03, respectively, for the nine months
ended September 30, 1997. Pro forma basic EPS and diluted EPS would have
been $(.01) and $(.01), respectively, for the three months ended September
30, 1996 and $.03 and $.03, respectively, for the nine months ended
September 30, 1996, respectively.
3. Discontinued Operations
-----------------------
On July 31, 1996, the Company sold all of the assets and liabilities of
Future Medical Technologies, Inc. ("FMT"), formerly a wholly owned
subsidiary, for $250,000 and certain royalty payments upon the sale of
certain products for up to five years. $25,000 of the selling price was
received in 1996 and the remaining balance is due in annual installments of
$25,000 (1997), $50,000 (1998 and 1999) and $100,000 (2000). Interest is
charged at 7% per annum. FMT was accounted for as discontinued operations
and accordingly, assets, liabilities and operations were segregated in the
accompanying consolidated balance sheet and statements of operations.
8
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
When used in this Report on Form 10-QSB and in other public statements, both
oral and written, by the Company and Company officers, the words "estimate,"
"project," "intend," "believe," "anticipate" and similar expressions are
intended to identify forward-looking statements regarding events and financial
trends that may affect the Company's future operating results and financial
position. Such statements are subject to risks and uncertainties that could
cause the Company's actual results and financial position to differ materially.
Such factors include, among others: (I) the Company's success in attracting new
business; (ii) the size, duration and timing of clinical trials; (iii) the
termination, delay or cancellation of clinical trials; (iv) the intense
competition in the industry in which the Company competes; (v) the Company's
ability to obtain financing on satisfactory terms; (vi) the sensitivity of the
Company's business to general economic conditions; and (vii) other economic,
competitive, governmental and technological factors affecting the Company's
operations, markets, products, services and prices. The Company undertakes no
obligation to publicly release the result of any revision of these forward-
looking statements to reflect events or circumstances after the date they are
made or to reflect the occurrence of unanticipated events.
The information set forth and discussed below for the three months and nine
months ended September 30, 1997 is derived from the Consolidated Financial
Statements included elsewhere herein. The financial information set forth and
discussed below is unaudited but, in the opinion of management, reflects all
adjustments (consisting of normal recurring accruals) necessary for a fair
presentation of such information. The results of operations of Covalent Group,
Inc. (the "Company") for a particular quarter may not be indicative of results
expected during the other quarters or for the entire year.
General
- -------
The Company and its wholly owned subsidiary Covalent Research Alliance Corp., is
a research management organization that designs, coordinates and monitors
clinical trials in drug development for some of the world's leading
pharmaceutical firms. In addition, using advanced technologies, the Company
works extensively in managed care, medical outcomes research and health
management programs that focus on compliance and provider/patient behavior
modification. Revenue is derived principally from the identification,
placement, monitoring and management of clinical development studies in the
traditional pharmaceutical, as well as managed care environment.
The Company's quarterly results can fluctuate as a result of a number of
factors, including the Company's success in attracting new business, the size
and duration of the clinical trials, the timing of client decisions to conduct
new clinical trials or possible cancellation or delays of ongoing trials, and
other factors, many of which are beyond the Company's control. Clinical
research service contracts generally have terms ranging from several months to
several years. A portion of the contract fee is generally payable upon
execution of the contract, with the balance payable in installments over the
life of the contract. Revenue and related cost of revenue are recognized as
specific contract terms are fulfilled under the percentage of completion method.
9
<PAGE>
Contracts generally may be terminated by clients with or without cause.
Clinical trials may be terminated or delayed for several reasons, including
unexpected results or adverse patient reactions to the drug, inadequate patient
enrollment or investigator recruitment, manufacturing problems resulting in
shortages of the drug or decisions by the client to de-emphasize or terminate a
particular trial or development efforts on a particular drug. Depending on the
size of the trial in question, a client's decision to terminate or delay a trial
in which the Company participates could have a materially adverse effect on the
Company's backlog, future revenue and profitability.
The Company's backlog, which consists of anticipated revenues from signed
contracts, is in excess of $13 million at September 30, 1997. The Company
believes that its backlog as of any date is not necessarily a meaningful
predictor of future results.
Three Months Ended September 30, 1997 Compared To The Three Months Ended
- ------------------------------------------------------------------------
September 30, 1996.
- -------------------
Revenues for the three months ended September 30, 1997 increased 32% to
$3,545,000 as compared to $2,687,000 for the three month period ended September
30, 1996. The increase of $858,000 is directly related to the number of
clinical studies being conducted.
Cost of revenues includes compensation and other expenses directly related to
conducting clinical studies. These costs increased $538,000 from $1,624,000 to
$2,162,000 for the three months ended September 30, 1996 and 1997, respectively.
Cost of revenues as a percentage of total revenues was 61% for the three months
ended September 30, 1997 and 60% for the same period last year.
Selling, general and administrative expenses include all administrative
personnel and business development, and all other support expenses not directly
related to specific contracts. Selling, general and administrative expenses for
the three months ended September 30, 1997 amounted to $584,000 as compared to
$557,000 for the same period last year. As a percentage of revenues, selling,
general and administrative expenses decreased from 21% to 16% for the three
month periods ended September 30, 1996 and 1997 respectively. The decrease in
expenses as a percentage of revenues results from the growth of clinical trial
services.
Research and development expenses for the three months ended September 30, 1997
amounted to $443,000 as compared to $291,000 for the same period last year and
relates to costs associated with developing an interactive voice recognition
system.
Other income increased $2,000 from $31,000 for the three months ended September
30, 1996 to $33,000 for the three months ended September 30, 1997. The increase
is a result of additional interest income.
Net loss from discontinued operations for the three month period ended September
30, 1996 amounted to $36,000 and relates to operations of Future Medical
Technologies Inc., ("FMT"), a subsidiary of the Company, which was sold to a
third party on July 26, 1996. All operating results associated with this
business have been reclassified as loss from discontinued operations for
financial reporting purposes. As a result of the sale, the Company incurred a
loss of $302,000 during the three month period ended September 30, 1996.
10
<PAGE>
Income taxes as a percentage of income from continuing operations before income
taxes amounted to 17% for the three months ended September 30, 1997 and is net
of a federal tax credit applicable to qualified research expenses. As a result
of the Company's net operating loss carry forward, the Company did not
anticipate a federal tax liability for 1996. Accordingly, the tax rate is not
reflected in the Company's Consolidated Statement of Operations for the three
months ended September 30, 1996.
Nine Months Ended September 30, 1997 Compared To The Nine Months Ended September
- --------------------------------------------------------------------------------
30, 1996.
- ---------
Revenues for the nine months ended September 30, 1997 increased 49% to
$9,859,000 as compared to $6,623,000 for the nine months ended September 30,
1996. The increase of $3,236,000 is directly related to the number of clinical
studies being conducted.
Cost of revenues includes compensation and other expenses directly related to
conducting clinical studies. These costs increased $3,227,000 from $3,797,000
to $7,024,000 for the nine month periods ended September 30, 1996 and 1997,
respectively. Cost of revenues as a percentage of total revenues was 71% for
the nine months ended September 30, 1997 as compared to 57% for the same period
last year. The increase in relative percent is due to the type of clinical
studies, the different cost structures of the studies, and costs of increased
personnel necessary to support an expected greater volume of clinical trials.
Selling, general and administrative expenses include all administrative
personnel and business development, and all other support expenses not directly
related to specific contracts. Selling, general and administrative expenses for
the nine months ended September 30, 1997 amounted to $1,766,000 as compared to
$1,505,000 for the same period last year. The increase in the level of expenses
of $261,000 is due to the overall expansion of the business and costs associated
with building the necessary support infrastructure. As a percentage of
revenues, selling, general and administrative expenses decreased from 23% to 18%
for the nine month periods ended September 30, 1996 and 1997 respectively. The
decrease in expenses as a percentage of revenues results from the growth of
clinical trial services.
Research and development expenses for the nine months ended September 30, 1997
amounted to $864,000 as compared to $590,000 for the same period last year. The
increase relates to costs associated with developing an interactive voice
recognition system.
Other income increased $18,000 from $65,000 for the nine months ended September
30, 1996 to $83,000 for the nine months ended September 30, 1997. The increase
is a result of additional interest income.
Net loss from discontinued operations for the nine month period ended September
30, 1996 amounted to $157,000 and relates to seven months of operations of FMT.
All results associated with this business have been reclassified as loss from
discontinued operations for financial reporting purposes. The financial impact
of this transaction resulted in a one time nonrecurring loss of $302,000 which
was charged to earnings in the quarter ended September 30, 1996.
11
<PAGE>
Income taxes as a percentage of income from continuing operations before income
taxes amounted to 23% (before the recording of the income tax benefit on the
sale of FMT) for the nine months ended September 30, 1997 and is net of a
federal tax credit applicable to qualified research expenses. In 1997, the
Company reached agreement with the purchaser to treat the sale of FMT as an
asset sale under Internal Revenue Code Section 338 (h)(10). Accordingly, the
loss on the disposition of FMT is deductible for tax purposes against future net
income. As a result, during the first quarter of 1997, the Company incurred an
additional deferred tax asset of $104,000. Management anticipates the loss on
disposition to be fully utilized. As a result of the Company's net operating
loss carry forward, the Company did not anticipate a federal tax liability for
1996. Accordingly, the tax rate is not reflected in the Company's Consolidated
Statement of Operations for the nine months ended September 30, 1996.
Liquidity and Capital Resources
- -------------------------------
The Company's contracts usually require a portion of the contract amount to be
paid at the time the contract is initiated. Additional payments are generally
made upon completion of negotiated performance requirements throughout the life
of the contract. Cash receipts do not necessarily correspond to costs incurred
and revenue recognized (revenue recognition is based on the percentage of
completion accounting method). The Company typically receives a low volume of
large-dollar receipts. As a result, the number of days outstanding in accounts
receivable will fluctuate due to the timing and size of cash receipts. Accounts
receivable including unbilled services to clients was $1,107,000 at September
30, 1997 as compared to $3,134,000 at December 31, 1996.
Cash provided by operating activities during the nine months ended September 30,
1997 was $1,374,000, as compared to $247,000 during the nine months ended
September 30, 1996. Accounts receivable decreased by $2,027,000 during the nine
months ended September 30, 1997. Costs and estimated earnings in excess of
related billings on uncompleted contracts increased by $2,531,000 and accounts
payable and accrued expenses increased by $1,931,000 during the nine months
ended September 30, 1997. These increases were due to the increase in revenues
experienced by the Company. Acquisitions of property and equipment were
$300,000 for the nine months ended September 30, 1997 as compared to $248,000
for the nine months ended September 30, 1996.
The Company has a line of credit with a commercial bank providing a maximum
credit facility of $1 million which bears interest at a rate not to exceed 1%
point above the bank's prime rate. Borrowings outstanding under the credit line
are secured by substantially all of the assets of the Company. No borrowings
were outstanding under the credit line at September 30, 1997.
The Company's principal cash needs on both a short and long-term basis are for
the funding of its operations, and capital expenditure requirements. The
Company expects to continue expanding its operations through internal growth,
expansion of its existing list of services, and the development of new service
products for clinical research and the healthcare industry. The Company expects
such activities to be funded from existing cash and cash equivalents and cash
flow from operations.
12
<PAGE>
FORM 10-QSB
COVALENT GROUP, INC.
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings
None.
ITEM 2. Changes in Securities
None.
ITEM 3. Defaults Upon Senior Securities
None.
ITEM 4. Submission of Matters to a Vote of Security Holders
On September 16, 1997, the Company held its Annual Meeting of
Stockholders during which the stockholders:
(1) Elected four nominees to serve as directors with terms continuing
until the next Annual Meeting of Stockholders in 1998. The votes cast
were as follows:
For Against Abstain
---------- ---------- ---------------
Bruce LaMont 10,611,905 3,963 700
William Robinson 10,611,905 3,963 700
Ivan Rubin 10,611,905 3,963 700
John Whittle 10,610,905 3,963 1,700
(2) Ratified the appointment of the firm of Arthur Andersen LLP as
independent auditors beginning on January 1, 1998 to examine the
accounts of the Company for the year ended December 31, 1997. The
votes cast were as follows:
For Against Abstain
------------ -------------------- -------------
Ratification of
Arthur Andersen LLP 10,609,157 4,093 3,318
ITEM 5. Other Information
None.
ITEM 6. Exhibits and Reports on Form 8-K
(a) Exhibits
27 Financial Data Schedule (in electronic format only)
(b) Reports on Form 8-K
None.
13
<PAGE>
SIGNATURES
In accordance with the requirements of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
COVALENT GROUP, INC.
Dated: November 10, 1997 By: /s/Bruce LaMont
----------------- ---------------
Bruce LaMont, President
and Chief Executive Officer
Dated: November 10, 1997 By: /s/William K. Robinson
----------------- ----------------------
William K. Robinson, Chief
Financial Officer
14
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> SEP-30-1997
<CASH> 2,081,986
<SECURITIES> 0
<RECEIVABLES> 1,107,367
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 6,095,785
<PP&E> 1,025,273
<DEPRECIATION> 326,172
<TOTAL-ASSETS> 6,994,782
<CURRENT-LIABILITIES> 2,875,369
<BONDS> 0
0
0
<COMMON> 11,701
<OTHER-SE> 9,169,279
<TOTAL-LIABILITY-AND-EQUITY> 6,994,783
<SALES> 9,858,680
<TOTAL-REVENUES> 9,858,680
<CGS> 7,024,257
<TOTAL-COSTS> 7,024,257
<OTHER-EXPENSES> 2,630,100
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 287,318
<INCOME-TAX> (36,754)
<INCOME-CONTINUING> 324,073
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 324,073
<EPS-PRIMARY> .03
<EPS-DILUTED> 0
</TABLE>
